Mergers & Acquisitions ·
Fulcrum Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger with Slate Medicines, Inc., on…
FULCFulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger with Slate Medicines, Inc., on August 16, 2026, to combine in an all-stock transaction intended as a tax-free reorganization. Pre-merger Fulcrum stockholders are expected to own approximately 5.0% of the combined company, while pre-merger Slate stockholders and concurrent investors will own 95.0%. The deal includes a $245 million concurrent private placement financing led by Frazier Life Sciences. Fulcrum expects to declare an aggregate cash dividend of $270 million to its existing shareholders prior to closing. The combined entity will operate as Slate Medicines, Inc., with Slate’s board serving as the new board and Gregory Oakes as CEO. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules for rare hematological disorders.